Citi Downgrades Rigel Pharmaceuticals (RIGL) to Neutral
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $36.81 -3.28%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 24 | New: 9
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 24 | New: 9
Join SI Premium – FREE
Citi downgraded Rigel Pharmaceuticals (NASDAQ: RIGL) from Buy to Neutral.
For an analyst ratings summary and ratings history on Rigel Pharmaceuticals click here. For more ratings news on Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $8.43 yesterday.
For an analyst ratings summary and ratings history on Rigel Pharmaceuticals click here. For more ratings news on Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $8.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Downgrades Dixon Technologies India Ltd (DIXON:IN) to Add (2)
- Freedom Broker Downgrades PBF Energy (PBF) to Sell
- Morgan Stanley Downgrades Mankind Pharma Ltd (MANKIND:IN) to Equalweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
